Raymond James Financial Services Advisors Inc. Buys 23,637 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Raymond James Financial Services Advisors Inc. grew its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCULFree Report) by 46.6% during the third quarter, Holdings Channel reports. The institutional investor owned 74,401 shares of the biopharmaceutical company’s stock after purchasing an additional 23,637 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Ocular Therapeutix were worth $234,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Summer Road LLC grew its stake in shares of Ocular Therapeutix by 0.4% during the fourth quarter. Summer Road LLC now owns 6,122,089 shares of the biopharmaceutical company’s stock valued at $17,203,000 after buying an additional 27,328 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Ocular Therapeutix by 7.0% during the second quarter. BlackRock Inc. now owns 5,262,920 shares of the biopharmaceutical company’s stock worth $27,157,000 after purchasing an additional 344,611 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Ocular Therapeutix by 2.9% during the first quarter. Vanguard Group Inc. now owns 4,195,406 shares of the biopharmaceutical company’s stock worth $20,768,000 after purchasing an additional 116,383 shares during the period. Deltec Asset Management LLC boosted its holdings in shares of Ocular Therapeutix by 4.4% during the third quarter. Deltec Asset Management LLC now owns 2,061,797 shares of the biopharmaceutical company’s stock worth $6,474,000 after purchasing an additional 87,000 shares during the period. Finally, State Street Corp boosted its holdings in shares of Ocular Therapeutix by 5.6% during the second quarter. State Street Corp now owns 1,576,213 shares of the biopharmaceutical company’s stock worth $8,133,000 after purchasing an additional 83,254 shares during the period. 54.42% of the stock is owned by institutional investors.

Ocular Therapeutix Stock Performance

Shares of OCUL opened at $4.92 on Wednesday. The company has a debt-to-equity ratio of 9.41, a current ratio of 4.03 and a quick ratio of 3.96. Ocular Therapeutix, Inc. has a one year low of $2.00 and a one year high of $7.96. The company has a 50-day simple moving average of $3.89 and a two-hundred day simple moving average of $3.58. The firm has a market capitalization of $390.75 million, a PE ratio of -4.32 and a beta of 1.02.

Ocular Therapeutix (NASDAQ:OCULGet Free Report) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.24). Ocular Therapeutix had a negative return on equity of 589.24% and a negative net margin of 116.18%. The company had revenue of $15.08 million during the quarter, compared to analysts’ expectations of $15.41 million. On average, analysts anticipate that Ocular Therapeutix, Inc. will post -1.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on OCUL shares. StockNews.com lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Monday. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Ocular Therapeutix in a report on Wednesday, October 4th.

Read Our Latest Report on Ocular Therapeutix

Ocular Therapeutix Company Profile

(Free Report)

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Further Reading

Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCULFree Report).

Institutional Ownership by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.